New Zealand's Living Cell Technologies Cleared For Phase II Diabetes Trials As Pig Herd Becomes More Famous
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Auckland-based Living Cell Technologies received the green light from New Zealand regulators to proceed with Phase II clinical trials of its lead product Diabecell, based on encapsulated pig insulin-producing cells aimed at normalizing blood glucose levels for people with type 1 diabetes